Structural basis for CD97 recognition of the decay-accelerating factor CD55 suggests mechanosensitive activation of adhesion GPCRs

Minghui Niu1, Shengzhao Xu, Jie Yang, Deqiang Yao, Na Li, Jie Yan, Guisheng Zhong, and Gaojie Song

From the 1Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China; 2Human Institute, ShanghaiTech University, Shanghai, China; 3National Facility for Protein Science in Shanghai, Zhangjiang Lab, Shanghai Advanced Research Institute, CAS, Shanghai, China; 4Department of Physics, National University of Singapore, Singapore

Edited by Peter Cresswell

The adhesion G protein–coupled receptor CD97 and its ligand complement decay-accelerating factor CD55 are important binding partners in the human immune system. Dysfunction in this binding has been linked to immune disorders such as multiple sclerosis and rheumatoid arthritis, as well as various cancers. Previous literature has indicated that the CD97 includes 3 to 5 epidermal growth factor (EGF) domains at its N terminus and these EGF domains can bind to the N-terminal short consensus repeat (SCR) domains of CD55. However, the details of this interaction remain elusive, especially why the CD55 binds with the highest affinity to the shortest isoform of CD97 (EGF1,2,5). Herein, we designed a chimeric expression construct with the EGF1,2,5 domains of CD97 and the SCR1–4 domains of CD55 connected by a flexible linker and determined the complex structure by crystallography. Our data reveal that the two proteins adopt an overall antiparallel binding mode involving the SCR1–3 domains of CD55 and all three EGF domains of CD97. Mutagenesis data confirmed the importance of EGF5 in the interaction and explained the binding specificity between CD55 and CD97. The architecture of CD55–CD97 binding mode together with kinetic suggests a force-resisting shearing stretch geometry when forces applied to the C termini of both proteins in the circulating environment. The potential of the CD55–CD97 complex to withstand tensile force may provide a basis for the mechanosensing mechanism for activation of adhesion G protein–coupled receptors.

Adhesion G protein–coupled receptors (GPCRs) are a subfamily of GPCRs that participate in a wide variety of functions from cell adhesion to immune defense and development, and, consequently, their dysfunction is linked to a myriad of negative health effects including inflammation, neurological disease, and cancer (1). Adhesion GPCRs are characterized by variable tandem adhesion domains followed by a common GPCR autophosphorylation-inducing (GAIN) domain at the extracellular region and a canonical seven-transmembrane (TM) domain at the C-terminal region (2). The epidermal growth factor (EGF) subgroup of the adhesion GPCR includes five members, CD97, and EGF module–containing mucin-like hormone receptor (EMR) numbers 1 through 4. Each of these members exhibits similar structural patterns but with variant numbers of EGF-like domains. Uniquely among the members, CD97 is widely expressed on granulocytes, monocytes, macrophage, dendritic cells, and smooth muscle cells (3). Recent in vivo studies using mAbs have indicated that CD97 plays a prominent role in neutrophil migration and antibacterial immunity (4). Furthermore, CD97 has also been identified as a tumor-associated receptor and it is significantly upregulated in many carcinomas, including gastric, colorectal, and pancreatic (5–7).

CD97 has three alternative gene-spliced isoforms containing between three and five EGF domains: EGF1,2,5, EGF1,2,3,5, and EGF1–5 (8). These isoforms have been linked to distinct functions, an aspect believed to derive from the different ligands they accommodate (9, 10). CD97 was first reported to bind CD55 (or decay-accelerating factor), a regulator of the complement system (11). Antibody blocking, domain deletion, and swapping experiments have verified the critical role of the first two EGF domains of CD97 in binding CD55 (12, 13). Conversely, the presence of EGF3–4 has been shown to reduce CD97 binding affinity with CD55. In addition to CD55, CD97 can also bind to a number of other ligands including CD90 (Thy1) (14) and integrins (15) α5β1 and αvβ3, which likely bind to the GAIN domain, as well as chondroitin sulfate B (16), which binds to the EGF4 domain. These varied binding partners, together with the different isoforms of CD97, likely associate with distinct physiological consequences.

CD55 is a GPI-linked membrane protein with four short consensus repeat (SCR) domains at the N terminus. CD55 regulates the complement cascade by inactivating the C3 convertases and plays a critical role in inflammation and pathogen defense (17). The binding of CD55 to CD97 can protect several cell types from complement-mediated damage, and the CD55–CD97 interactions are involved in the

*For correspondence: Gaojie Song, gjsong@bio.ecnu.edu.cn.
Complex structure of CD97–CD55

pathogenesis for multiple sclerosis (18), synovial inflammation, and rheumatoid arthritis (19). CD55 is also linked to adaptive immunity via costimulating CD4+ T cells with CD97, resulting in T cell activation and an increase in cell proliferation and cytokine secretion (20).

CD97 shares the highest similarity with EMR2 in the primary sequence, with only three residual differences in EGF domains 1, 2, and 5. However, EMR2 (EGF1,2,5) has been found to bind to CD55 with a dissociation constant ($K_D$) much lower (>10 fold) than that of CD97 (EGF1,2,5) (13, 21). Crystal structures of the SCR domains of CD55 (22) and the EGF1,2,5 domains of EMR2 (23) reveal an extended rod-like conformation. However, owing to the absence of crystal structure for CD55 in complex with CD97 or EMR2, insights into the binding mode and specificity, as well as the signal transduction mediated by the ligand-receptor pair, remain elusive. Herein, we report the structure of the adhesive domains of the CD97–CD55 complex as determined at 3.19 Å resolution by X-ray crystallography. Evaluation of the complex structure reveals not just an overall antiparallel binding mode but also the specificity for CD97 recognition by CD55.

Results

Structural determination

The CD55 SCR1–4 domains and CD97 EGF1,2,5 domains were initially purified independently from HEK293 cells. However, the mixture of the two fragments did not yield a stable complex in gel-filtration chromatography, presumably because of the relatively low affinity between the two proteins. Therefore, we designed a 24-residue linker including a tobacco etch virus protease (TEV) site to connect the C terminus of EGF1,2,5 and the N terminus of SCR1–4, enlightened by a head-to-tail docking mode based on NMR titration (Experimental procedures, Fig. 1A) (13, 23). The chimeric construct was then expressed and purified to homogeneity (Fig. 1, B and C). Cleavage of the linker with TEV generated a size-exclusion profile of two peaks corresponding to the CD55 and CD97 fragments, suggesting each protein within the chimera construct was well folded individually (Fig. 1C). The small-angle X-ray scattering (SAXS) measurements and alignments with models of the chimera complex and each individual protein indicated the formation of a stable CD55–CD97 complex, mediated by the flexible linker (Fig. 1D, Fig. S1 and Table S1). We then successfully crystallized the chimeric

Figure 1. Structural determination of the CD97–CD55 complex. A, the CD97–CD55 binding pattern and our chimeric construct. B, SDS-PAGE of individual adhesive domains of CD97 or CD55 or the chimeric CD97–24a–CD55 complex. C, size-exclusion profiles of above three proteins as well as the chimeric protein digested by TEV. The elution volume of bovine serum albumin (66 kDa) was indicated as a control. D, SAXS analysis of above three proteins and alignments with previously determined crystal structures of EMR2 (2bo2) and CD55 (1ojv) and crystal structure determined in the present study (CD97–24a–CD55 chimeric complex). Normalized structural difference (NSD) was indicated for each sample. E, superposition of the CD97–CD55 complex with previous individual monomers. Monomers of CD97 are from PDB IDs 2bo2, 2box, and 2bou. Monomers of CD55 are from PDB IDs 1ojv, 1ojy, and 1ojw. CD97 and CD55 in the complex are colored pink and green, respectively, while other monomers are in light colors. EMR, EGF module–containing mucin-like hormone receptor; SAXS, small-angle X-ray scattering.
Complex and collected the data to 3.19 Å resolution. We solved the structure with molecular replacement using previous high-resolution structures of CD55 and EMR2 as searching models, and the final structure was refined to R_work and R_free of 0.26 and 0.30, respectively (Table 1).

Although most of the residues in the complex can be successfully modeled, the linker region is disordered, consistent with its highly hydrophilic property. Crystal packing revealed two major crystal lattices with packing interfaces of 960 Å² and 748 Å², named lattice A and lattice B, respectively (Fig. S2A).

Previous binding studies of CD55 and CD97 have emphasized the importance of the N-terminal domains of both proteins in recognition, and our designed 24-residue linker was sufficient to connect the 36 Å distance between the C terminus of EGF1,2,5 and the N terminus of SCR1,4 in lattice A but not long enough to fill the 106 Å gap in lattice B. Furthermore, lattice A binding mode can be fitted into a SAXS envelop with a normalized structural difference of 2.74; this is relatively better than the resolution envelope calculated from scattering data, we cannot rule out another possibility of an ensemble fit (24) for the chimeric complex in the solution. Therefore, the surface plasmon resonance (SPR) binding studies have been conducted to further support the lattice A binding mode (see below). All these analyses clearly favor physiological relevance of the binding mode in lattice A over lattice B and we therefore only discuss the lattice A binding mode hereafter.

**Binding mode**

The CD55 and CD97 bind roughly antiparallel to each other involving each N-terminal tandem domains (Fig. 1E). Structures of CD55 and CD97 in the complex superimposed closely with prior monomeric structures, with a Cα r.m.s.d. of 0.9 to 2.1 Å and 1.1 to 1.2, respectively (Fig. 1E), suggesting no conformational change is needed during binding. Previous structures of CD55 SCR domains have suggested a constant interface of SCR2–SCR3 and very little variation in the interfaces of SCR1–SCR2 and SCR3–SCR4. In our complex structure, the orientation of SCR2–SCR3 is invariant and the other interfaces are within similar ranges of variation as the CD55 molecules of previous studies (Fig. 1E). Similar case in CD97, only slight variation in the EGF1–EGF2 or EGF2–EGF5 interface, is monitored when compared with previous monomeric structures of its homolog protein, EMR2 (Fig. 1E). In CD97 or EMR2, EGF2 and EGF3 each bind a calcium ion in the N-terminal tip, which contributes to rigidity within the interface of EGF1–EGF2 or EGF2–EGF5. These comparisons, together with apparent disorder of the 24-residue linker between the two molecules, indicated the binding mode between CD55 and CD97 is not affected by the protein engineering. The total solvent-accessible surface buried by the EGF1,2,5–SCR1,4 interactions was 1920 Å², an interface area that is above the average for protein–protein interaction (25). All domains, except SCR4, are involved in the CD97–CD55 interaction, and this is the probable reason that SCR4 possesses relatively poor electronic density compared with other domains in the complex. Our examination of the SCR4 domain revealed that only 20% of its surface area are buried by lattice contact, in contrast to 30% to 39% for the other SCR domains. Our complex structure reveals two N-glycosylation sites in CD97 (Asn-38 and Asn-108) and one N-glycosylation site in CD55 (Asn-95), but none of these carbohydrates are involved in the CD97–CD55 interactions.

The EGF1,2,5–SCR1,4 interactions can be divided into three interfaces: the EGF1–SCR3/SCR interface, the EGF2–SCR1/SCR2 interface, and the EGF3–SCR1 interface (Fig. 2). In the EGF1–SCR2/SCR interface, we observed that Asp-63 of EGF1 forms a charged hydrogen bond with Arg-130 of SCR2 (Fig. 2A). In addition, EGF1 also forms extensive hydrophobic interactions with SCR2 and SCR3 residues and buries a total surface area of 518 Å². The preeminent interactions of CD97–CD55 come from the EGF2–SCR1/SCR2 interface in the middle region, which buries a total surface area of 1278 Å² and contains six pairs of hydrogen bonds (Fig. 2B). At the upper half of this interface, Thr-70 and Glu-86 of EGF2 hydrogen bond to Gln-99 and Gln-111 of SCR2, respectively. In addition, the carbonyl group of Cys-82 in EGF2 forms a hydrogen bond to Asn-117 of SCR2. At the bottom half of the interface, the EGF2–SCR1 interactions are secured by three pairs of side chain–main chain hydrogen bonds between EGF2 residues Asp-79, Asp-80, and Asp-81 and SCR1 residues Asp-77, Lys-71, and Lys-74, respectively. In the third interface of EGF5–SCR5 (Fig. 2C), Val-137 of EGF5 inserts into a joint hydrophobic pocket formed by SCR1 residues Val-60, Lys-76, Val-79, Ile-80, and Leu-82 and EGF2 residue Phe-79. These interfaces are consistent with previous literature, identifying the EGF1,2 and SCR1,4 domains as critical determinants for CD55–CD97 interactions. Moreover, our structure unveils additional interactions contributed by EGF5 of CD97 as well as

**Table 1**

| Data collection and refinement statistics | CD97–CD55 complex |
|-----------------------------------------|-------------------|
| Data collection                         | P2₁               |
| Space group                             |                   |
| Cell dimensions                         | a, b, c (Å)       |
|                                         | 51.80, 44.25, 116.53 |
|                                         | a, β, γ ()        |
|                                         | 90.0, 89.68, 90.0 |
| Resolution (Å)                          | 33.23–3.19 (3.27–3.19) |
| Reflections (total/unique)              | 33,704/8903       |
| Rmerge                                  | 0.14 (0.77)       |
| C1/2                                    | 0.98 (0.89)       |
| R(free)                                 | 7.3 (2.2)         |
| Completeness (%)                        | 99.2 (98.3)       |
| Redundancy                               | 3.8 (4.0)         |
| Refinement                              |                   |
| Rwork/Rfree                             | 0.267/0.304       |
| R.m.s.d.                                |                   |
| Bond lengths (Å)                        | 0.004             |
| Bond angles (°)                         | 0.899             |
| Ramachandran (%) plot (%)              | 93.5/65.0         |
| Residue range                           | A/CD97/25–164; B/CD55/35–284 |
| Carbohydrate residues                   | 4                 |
| Metal ion                               | 2 calcium         |
| PDB ID                                  | 7DO4              |

*Values for the highest resolution shells are given in parentheses.

a Rmerge = Σhkl ||I(hkl) − <I(hkl)>||/Σhkl ||I(hkl)||, where I(hkl) and <I(hkl)> are the i and mean measurement of intensity of reflection hkl, respectively.

b CC1/2 = Pearson’s correlation coefficient between average intensities of random half data sets for each unique reflection.
SCR$_3$ of CD55. Notably, the involvement of EGF$_5$ in the CD55–CD97 interactions may elucidate why the EGF$_{1,2,5}$ isoform of CD97 shows a higher binding affinity to CD55 than the other two isoforms, EGF$_{1,2,3,5}$ and EGF$_{1–5}$.

The relatively large interface in the CD55–CD97 complex appears to be inconsistent with the previously characterized low affinity and rapid off-rate binding (13, 25). To understand this puzzle, we remeasured the binding kinetics of CD55 and CD97 by SPR. We preimmobilized His-tagged CD55 onto a nickel coated NTA sensor chip and sequentially injected serial concentrations of CD97 samples. Our results show that CD97 binds to CD55 with a $K_D$ of 3.2 $\mu$M, 20-fold higher than the previously reported affinity (Fig. 3A), and in accord with one study demonstrating a statistical correlation between the interface area and binding affinity (25). Furthermore, compared with the previously determined fast off-rate (13), our measurements show the two proteins bound to each other with a much slower on-rate ($546$ M$^{-1}$S$^{-1}$) and off-rate ($1.73 \times 10^{-3}$S$^{-1}$). These rates are in line with our structural observation of the antiparallel binding interface that composed by tandem rod-like domains at both sides. The apparent difference in binding kinetics between our measurements and previous reports could be attributed to the differing immobilization techniques. In the previous work, CD55 was randomly covalently attached to the chip via primary amino groups, which may cause a decrease in flexibility.

Figure 2. The detailed interactions of CD97–CD55. A–C, the detailed interactions of EGF$_1$–SCR$_2$/SCR$_3$ (A), EGF$_2$–SCR$_1$/SCR$_2$ (B), EGF$_5$–SCR$_1$ (C) interfaces. CD97 and CD55 domains are colored pink and green, respectively. Interacting residues are shown as sticks and labeled. Dashed lines indicate hydrogen bonds. Yellow spheres represent coordinated calcium. EGF, epidermal growth factor; SCR, short consensus repeat.
and accessibility by CD97 (13). Moreover, our proteins were both expressed and secreted from HEK293 cells, whereas in the previous work, the CD97 and CD55 proteins were expressed from *Escherichia coli* or *Pichia* (13).

We further measured affinity of CD97 mutants to confirm the physiological relevance of the binding mode. Within the interface, D63, D81, and E86 of CD97 each hydrogen bonds to a residue in CD55 (Fig. 2). Aligned with this interface, the binding affinity of mutants D63L (85.17 ± 2.43 μM), D81A (66.37 ± 21.38 μM), and E86A (17.56 ± 2.04 μM) decreased by 26-, 20-, and 5-fold, respectively (Fig. 3, B–D).

### Structural specificity for CD97 recognition by CD55

The CD55–CD97 interface defined in our structure does not overlap with the interface proposed from NMR titration (23). In the previous model, the SCR1 and N-terminal portion of SCR2 in CD55 bind to the other side of CD97 with a much smaller interface (Fig. S3). Furthermore, that model does not

---

**Figure 3.** SPR measurements of WT and mutated CD97 with CD55. SPR sensorgrams (colored lines) are shown with fits (black lines). CD55 was immobilized in the NTA chip and titrated with indicated concentrations of CD97 (A–E) or EMR2 (F). Kinetic values are indicated above the curves. Values are the mean ± difference from the mean of two independent experiments. SPR, surface plasmon resonance.
explain how such a minute difference between CD97 and EMR2 could dramatically alter the ligand-binding affinity. It also cannot explain why the smallest isoform of CD97 has the highest binding affinity with CD55. In a further demonstration that the previous model is untenable, it locates all three carbohydrates in the binding interface (Fig. S3); the protein samples used for the NMR titration are nonglycosylated as they were generated from E. coli. In contrast, our crystal structure reveals key features that illuminate the specificities for CD55 recognition by different splicing isoforms of CD97 as well as its homologues.

Although the interface involved by EGF3 (194 Å2) is relatively small—and no hydrogen bond is visualized within this interface—this EGF domain may dictate the binding affinity and specificity of the different CD97 isoforms with CD55. In the EGF1,2,3,5 and EGF1,5 isoforms, the EGF3 domain occupies the position of EGF5 and faces the SCR1 domain of CD55. The key EGF5 residue Val-137 is equivalent to a leucine residue in the EGF3 domain. The relative conservation of this position suggests that in the other two isoforms, the EGF3 domain may involve in the binding of CD55 with similar pattern. To further verify the importance of a hydrophobic aliphatic residue in the interface with CD55, we mutated the V137 to an alanine in the EGF1,2,5 fragment and the SPR result showed that the V137A mutant shows an ~8-fold reduction in binding value (25.3 ± 2.35 μM), confirming the involvement of these variant residues in the binding interactions (Fig. 3E). The additional methylene group in the EGF3 domain, together with a potential fine-tuning of its orientation compared with the first two EGF domains, may contribute to lower binding affinity of the two longer isoforms (EGF1,2,3,5 and EGF1,5) than the EGF1,2,5 isoform.

The EGF1,2,5 fragment of CD97 and EMR2 is differentiated by only three residues, and previous reference suggested >10-fold lower CD55-binding affinity of EMR2 than CD97 (13). Although with different values, our measurements of EMR2 EGF1,2,5 fragment indicated similar level of reduction in binding affinity (43.04 ± 6.28 μM), confirming the involvement of these variant residues in the binding interactions (Fig. 3F). Two of three variant residues are located in the binding interface with CD55, and their side chains can be unambiguously modeled in the CD97–CD55 complex (Fig. 4). The first variation is located in the EGF1–SCR2/SCR3 interface, whereas similar interaction would be absent in the EMR2–CD55 interface (Fig. 4, A and B). The second differing residue is located in a thermal-dynamic loop region in each EGF3 domain. In CD97, the Pro-71 and its preceding residue Thr-70 adopt a cis-conformation, allowing the Thr-70 to form a hydrogen bond to Glu-99 in the CD55 SCR2 domain (Fig. 4, A and C). A cis-peptide conformation is not allowed in EMR2, as the equivalent residue of Pro-71 is Leu-74. Remarkably, in EMR2, the Leu-74 occupies the position

Figure 4. Comparison of CD97 and EMR2 in their binding with CD55. A, for comparison, structure of EMR2 (2bo2) is superimposed to the CD97 EGF domains of the complex. CD97, EMR2, and CD55 are colored pink, dark yellow, and green, respectively. Variant residues are underlined, and other key residues are shown as sticks and marked. The double-headed arrow indicates conformational change of the loop bearing key different residues between CD97 (P71) and EMR2 (L74). B and C, electronic densities around the variant residues of CD97 and their interacting residues on CD55 are shown at 2Fo − Fc of 1σ. Elements from EMR2 are also shown in panels B and C for comparison. EGF, epidermal growth factor; EMR, EGF module–containing mucin-like hormone receptor.
of CD97 residue Thr-70, and therefore, no hydrogen bond is formed in this region when it binds to CD55. The third residue difference, Asn-33/Asp-36, is not located in the binding interface, so it may not directly affect the binding of CD97–EMR2 with CD55.

There are conservations, as well as specializations, in the CD97–CD55 interface between different mammalian species. The hydrogen-bonded residues of CD97, Asp-63 and Glu-86, are invariably Asp/Glu in all species, whereas Asp-81 is mostly conserved but replaced by a Met in rodents (Fig. 5A). In CD55, the hydrogen-bonded Asn-117 and Arg-130 are absolutely conserved, and Lys-71 and Asp-77 are highly conserved, except in rodents where they are replaced by Gln and Asn, respectively (Fig. S5). Other hydrogen-bonded residues, including Thr-70 of CD97 and Gln-99 and Gln-111 of CD55, are relatively diverse among species. Remarkably, these unique residues in rodents locate mostly in the EGF2–SCR1 interface, indicating substantial specialization in the rodent interface. In line with this specialization, previous references have shown that the CD97–CD55 interaction is species restricted and no cross-reaction is found between human and mouse agents (26, 27). Similar to human CD97, mouse CD97 also includes three isoforms but with slightly different organization: EGF1,2,4, EGF1,2,3,4, and EGF1,2,x,3,4 (X refers to a sequence of 45-residues that shows no homolog to any known module) (Fig. S4) (27). It will be interesting to know how the X module may affect the domain orientation and binding specialization with CD55. Despite these specializations, the physiologic function of the CD97–CD55 interaction was proved to be conservative between humans and rodents (19, 28, 29).

Domain organization of CD97, CD55, and their complex

Within the three structured EGF domains of CD97, EGF1 is immediately different from the other two domains because of its shorter β-sheet (Fig. 5A and D). The EGF1–EGF2 and EGF2–EGF3 interfaces are almost identical, featuring a main chain–main chain hydrogen bond and a van der Waals interaction between a glycine residue (Gly-87/Gly-138) in the β-turn of the EGF2 or EGF3 domain and a conserved aromatic residue (Phe-48/Tyr-97) in the precedent domain (Fig. 5, B–D). The aromatic and the non–side-chain glycine residues are also conserved in the EGF2 and EGF4 domains (Fig. 5D), indicating similar domain orientations in the EGF1,2,3,5 and EGF1–5 isoforms. CD55 also contains similar van der Waals interactions between the preceding SCR2 (Gly-132) and SCR3 (Gly-193) domains and their following SCR3 (Phe-182) and SCR4 (Tyr-245) domains (Fig. 5, E–G), respectively. Moreover, the van der Waals interactions in the SCR2–SCR3 and SCR3–SCR4 interfaces are each surrounded by additional hydrophobic residues that strengthen each interface. Nevertheless, in the SCR1 and SCR2 domains, the corresponding aromatic residues (Phe-55/Phe-119) are flipped and pointed toward the hydrophobic core of each domain (Fig. 5, E–H). Furthermore, the glycine residue is not conserved in SCR1 and its replacement by a serine residue generates a perturbation in the hydrophobic cage, making an orientation similar to SCR2/SCR3 or SCR3/SCR4 energetically unfavorable (Fig. 5, H and I).

To expose the hydrophilic Ser-68, the SCR1 is tilted about 45° to make contact with SCR2; this is in contrast to roughly straight orientations between the other SCR domains. The SCR1–SCR2 contact buries a total surface area of 560 Å², the largest among all interdomain contacts in CD55 or CD97.

Together with SCR2, the tilted SCR1 appears like a hook that holds the body of the CD97 EGF2 domain. The majority of the interactions of CD55 with CD97 come from this SCR1–SCR2 pair, including six of the seven total hydrogen bonds between the two proteins. One example is the Thr-70 bearing loop of CD97 EGF2 domain, which reaches deep into the hook and hydrophobic bonds to the Gly-99 of CD55 (Fig. 2). In addition, CD55 has a unique α-helix in the SCR2 domain that interacts and complements the first strand of EGF2 in CD97 (Fig. 5I). Adjacent to the hook is a conserved SCR2/SCR3 pair that generates a mostly hydrophobic patch engaging the EGF1 domain. Such domain pairs playing important roles for ligand binding are not uncommon and have been observed in the case of CD46 (30, 31). Both CD55 and CD97 contain 3 to 5 residues in the interdomain linkers, and these shorter linkers enable numerous interdomain contacts and constant domain orientations. These sequence and structural features elucidate the unique orientations of both the EGF and SCR domains, which facilitate an elongated and complementary interface between CD55 and CD97.

Discussion

The CD55–CD97 pair has been indicated to play an important role in host defense and inflammation, as they can mediate cell adhesion and prevent the uncontrolled clustering of leukocytes in the blood stream (20, 32). Specifically, during inflammation conditions, leukocytes bearing CD97 are targeted toward and adhere to the inflammation site through multiple contacts including the CD55–CD97 pair. Despite a slow on-rate, CD97 is in close proximity distance to CD55 during cell adhesion and clustering; thereby, fast formation of a linkage between these two molecules is feasible as a result of high local concentration. The overall architecture of the CD55–CD97 binding mode together with structural details leads to a shearing stretch geometry, which is known to resist force applied to the protein interface (33). For example, the first strand of EGF2 forms several hydrogen bonds with CD55; this strand adopts the most force-resistant orientation, which is parallel to the force vector through the C termini of CD55 and CD97, thus can hardly be peeled off. It is therefore reasonable to assume that the slow off-rate of the CD55–CD97 complex (1.73 × 10⁻⁹ s⁻¹ measured by SPR) is retained over a significant force range. The potential capability of withstanding a significant range of mechanical force suggests that the CD55–CD97 may mediate force transmission to the following GAIN domain, which is believed to be important for the function of adhesion GPCRs. For many adhesion GPCRs,
the 7TM domain is noncovalently associated with the extracellular region through its very N-terminal fragment (also called Stachel sequence, or tethered agonist) that inserts into a β-sheet module of the extracellular GAIN domain (2, 34). The transmitted shear force may induce a conformational change of the GAIN domain and separate it from the Stachel sequence (Fig. S6). Therefore, when leukocytes become overclustered, CD97 could be downregulated upon mechanically releasing its extracellular region from the cell membrane. Through this mechanism, uncontrolled clustering of leukocytes can be avoided in the circulation (32). Importantly, the mechanically exposed Stachel sequence has been testi- 

Figure 5. Sequence analysis of the complemented CD97–CD55 binding mode. A, alignment of the three EGF domains within CD97. B and C, interactions of the interdomain EGF1–EGF2 and EGF2–EGF5 interfaces. D, sequence alignment of all five EGF domains of CD97. E, superposition of SCR domains of CD55. F–H, CD55 interdomain interfaces. I, sequence alignment of all four SCR domains of CD55. Color codes are shown at the top right. Interacting residues are shown as sticks and labeled, while in panels F–H, the key G193/G132/S68 residues are shown as spheres. In panels D and I, thick lines indicate disulphide bonds, while cyan and red thin lines indicate α-helices and β-strands, respectively. In panels A–D, the conserved aromatic residues and glycine residues are marked red, while in panels E–I, the structurally unconserved aromatic residues F55/F119 or hydrophilic S68 are marked cyan. EGF, epidermal growth factor; SCR, short consensus repeat.
7TM domains for downstream signaling (Fig. S6). Nonetheless, mechanical force was reported to induce phosphorylation in the CD97 intracellular PDZ-binding motif, thus triggering a G protein–independent pathway (40). The concept of mechanosensing mechanism for adhesion GPCRs has been proposed previously (41–44); the present study is in favor of that force-induced signaling upon revealing an empirical force-resisting ligand-binding geometry. Given the relevance of the CD55–CD97 complex in immune disorders and carcinomas, elucidating this unique complex structure may provide insights for pharmaceutical development and a greater understanding of the mechanisms of the human body’s signaling pathways.

**Experimental procedures**

**Protein production and purification**

The CD97 (UniProt: P48960) EGF domains, CD55 (UniProt: P08174) SCR domains, and chimeric complex were expressed and purified as previously described (45). Briefly, the codon-optimized EGF1,2,5 isoform of CD97 (21–165), CD55 (35–285), or chimeric complex gene was inserted into a customized pLEXm (46) vector with N-terminal signal peptide and C-terminal His6 tags. In the chimeric construct (named CD97–24a–CD55), a 24-residue linker (GSGENLYFQSGSSSSGWRGGHVGS) was added to link the C terminus of EGF3 and the N terminus of SCR1. HEK293S GntT were cultured to 1 to 2 million/ml in suspension and were transiently transfected with DNA: polyethylenimine at 1:3 wt/wt. Culture supernatants were harvested after 3 to 4 days. Purification was with nickel coated NTA affinity followed by Superdex S200 increase gel filtration in 20 mM Tris, pH 7.5, 200 mM NaCl, and 2 mM CaCl2. The three purified proteins were subjected to SAXS analysis, and chimeric complex was concentrated to 16 mg/ml for crystallization trials. In the SPR measurements, the EGF1,2,5 (24–168) fragment of EMR2 (UniProt: Q9UHX3) and the EGF1,2,5 fragment of CD97 were cloned to the same vector as above except a TEV protease site was inserted after each gene sequence to remove the C-terminal His6 tag during purification. Single point-mutation fragments of CD97 were made by overlapping PCR and cloned to the same vector for expression and purification.

**SAXS**

SAXS experiments were performed at beamline BL19U2 of the National Facility for Protein Science Shanghai (NFPS) at Shanghai Synchrotron Radiation Facility. The wavelength (λ) of X-ray radiation was set as 0.918 Å. Scattered X-ray intensities were collected using a Pilatus 1M detector (Dectris Ltd). The sample-to-detector distance was set such that the detecting range of momentum transfer \( q = 4\pi \sin \theta / \lambda \), where \( 2\theta \) is the scattering angle \( \) of SAXS experiments was 0.008 to 0.47 Å⁻¹. To reduce the radiation damage, a flow cell made of a cylindrical quartz capillary with a diameter of 1.5 mm and a wall of 10 μm was used. SAXS data were collected as 20 x 1 s exposures, and scattering profiles for the 20 passes were compared at 10 °C using 60 μl sample in 20 mM Tris, pH 7.5, 200 mM NaCl, and 2 mM CaCl2. Measurements were carried out at two different concentrations in all cases using concentrations between 0.5 and 2 mg/ml. The 2D scattering images were converted to 1D SAXS curves through azimuthally averaging after solid angle correction and then normalizing with the intensity of the transmitted x-ray beam, using the software package Bio-XTAS RAW (47). The scattering data were binned over an interval of 7 pixel data points, and the background scattering was subtracted using PRIMUS in ATSAS software package (48). Pair distance distribution functions of the particles \( P(r) \) and the maximum sizes \( D_{max} \) were computed using GNOM (49). The \textit{ab initio} shapes were determined using GASBOR (50). SAXS data collection, analysis, and modeling fitting are summarized in Table S1.

**Crystallization and structure determination**

The concentrated CD97–24a–CD55 complex was set up for crystallization using hanging drop with NT8 (Formulatrix). Diffraction-quality crystals were produced at 18 °C in 0.1 M MES, pH 6.5, and 12% to 15% w/v PEG 20000. Another linker with six repeats of GSGP (GSGPGSGPGSPGSGP) also yielded thin crystals in similar conditions, but we happened to optimize better crystals from the CD97–24a–CD55 construct. In contrast, a shorter linker with 18 residues (GSGGSGGSGGSGGSGGSG) did not crystallize in the same condition. Single crystals were directly frozen in liquid nitrogen. Diffraction data were collected at a wavelength of 0.979 Å at beamline BL17U1 at the Shanghai Synchrotron Radiation Facility and indexed, integrated, and scaled using the automatic XIA2 software package (51). The structure was solved by the molecular replacement method using structures of CD55 (1ojv) and EMR2 (2bo2) as the search model simultaneously. Refinement was carried out using Phenix (52) and with manual adjustments with Coot (53). Refinement parameters are summarized in Table 1.

**SPR measurement**

For SPR experiments using Biacore T200 (GE Healthcare), His-tagged CD55 was immobilized on a nickel coated NTA chips. WT and mutant CD97 (without His-tag) were gel-filtered using Superdex 75 increase to remove aggregates before use. Protein was injected at 50 μl/min for 2 min in a buffer containing 20 mM Tris, pH 7.5, 200 mM NaCl, 2 mM CaCl2, and 0.05% Tween 20. The surface was regenerated with 4 M MgCl2 for 4 min at the end of each cycle to restore resource units to baseline. All traces were corrected for refractive index changes by subtraction of a control trace simultaneously recorded from a mock-immobilized channel. Kinetics and affinity analysis were performed with SPR evaluation software (GE Healthcare).

**Data availability**

Atomic coordinates and structure factors for the CD97–CD55 structure have been deposited in the Protein Data Bank with identification code 7DO4. Correspondence and requests...
Complex structure of CD97–CD55

for materials should be addressed to gjsong@bio.ecnu.edu.cn (Gaojie Song).

Supporting information—This article contains supporting information (23).

Acknowledgments—We thank the help on data collection provided from scientists of beamlines BL17U1 and BL19U2 at the Shanghai Synchrotron Radiation Facility. We thank Dr Yueming Xu for the information (23).

Author contributions—M. N. optimized constructs, expressed and purified proteins, crystallized and determined the structure, did the SPR measurements, and provided input for the article; S. X. assisted in molecular cloning and protein purification; Jie Yang assisted in SPR experiments. D. Y. helped in crystal data process and structure refinement; N. L. collected SAXS data and did modeling fitting; Jie Yan and G. Z. provided advice on the project and edited the manuscript; G. S. designed the construct, conceived the overall project, and wrote the manuscript. All authors were involved in the discussions and provided comments on the article.

Funding and additional information—This work was supported by the National Key Research and Development Program of China (2018YFA0507001) and the National Nature Science Foundation of China Grant 31770898 (to G. S.).

Conflict of interests—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: 7TM, seven-transmembrane; EGF, epidermal growth factor; EMR, EGF module–containing mucin-like hormone receptor; GAIN, GPCR autopoiesis-inducing; GPCRs, G protein–coupled receptors; SAXS, small-angle X-ray scattering; SCR, short consensus repeat; SPR, surface plasmon resonance; TEV, tobacco etch virus.

References
1. Langenhani, T. (2020) Adhesion G protein-coupled receptors-candidate metabotropic mechanosensors and novel drug targets. Basic Clin. Pharmacol. Toxicol. 126 Suppl 6, 5–16
2. Langenhani, T., Aust, G., and Hamann, J. (2013) Sticky signaling—adhesion class G protein-coupled receptors take the stage. Sci. Signal. 6, re3
3. Jaspars, L. H., Vos, W., Aust, G., Van Lier, R. A., and Hamann, J. (2001) Tissue distribution of the human CD97 EGF-TM7 receptor. Tissue Antigens 57, 325–331
4. Leemans, J. C., te Velde, A. A., Florquin, S., Bennink, R. J., de Bruin, K., van Lier, R. A., van der Poll, T., and Hamann, J. (2004) The epidermal growth factor-seven transmembrane (EGF-TM7) receptor CD97 is required for neutrophil migration and host defense. J. Immunol. 172, 1125–1131
5. Aust, G., Eichler, W., Laue, S., Lehmann, I., Heldin, N. E., Lotz, O., Scherbaum, W. A., Dralle, H., and Hoang-Vu, C. (1997) CD97: A differentiation marker in human thyroid carcinomas. Cancer Res. 57, 1798–1806
6. Steinert, M., Wobus, M., Boltze, C., Schutz, A., Wahlbuhl, M., Hamann, J., and Aust, G. (2002) Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am. J. Pathol. 161, 1657–1667
7. Aust, G., Steinert, M., Schutz, A., Boltze, C., Wahlbuhl, M., Hamann, J., and Wobus, M. (2002) CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. Am. J. Clin. Pathol. 118, 699–707
8. Gray, J. X., Haino, M., Roth, M. J., Maguire, J. E., Jensen, P. N., Yarme, A., Stetler-Stevenson, M. A., Siebenlist, U., and Kelly, K. (1996) CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J. Immunol. 157, 5438–5447
9. Liu, D., Trojanowicz, B., Ye, L., Li, C., Zhang, L., Li, X., Li, G., Zheng, Y., and Chen, L. (2012) The invasion and metastasis promotion role of CD97 small isomor in gastric carcinoma. PLoS One 7, e39989
10. Eichler, W. (2000) CD97 isomorphism in leukocytes. J. Leukoc. Biol. 68, 561–567
11. Hamann, J., Vogel, B., van Schijndel, G. M., and van Lier, R. A. (1996) The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J. Exp. Med. 184, 1185–1189
12. Hamann, J., Stortelers, C., Kiss-Toth, E., Vogel, B., Eichler, W., and van Lier, R. A. (1998) Characterization of the CD97(DAF)-binding site on the seven-span transmembrane receptor CD97. Eur. J. Immunol. 28, 1701–1707
13. Lin, H. H., Stacey, M., Saxby, C., Knott, V., Chaudhry, Y., Evans, D., Gordon, S., McKnight, A. J., Handford, P., and Lea, S. (2001) Molecular analysis of the epidermal growth factor-like short consensus repeat domain-mediated protein-protein interactions: Dissection of the CD97–CD55 complex. J. Biol. Chem. 276, 24160–24169
14. Wandel, E., Saalbach, A., Sittig, D., Gebhardt, C., and Aust, G. (2012) Thy-1 (CD90) is an interacting partner for CD97 on activated endothelial cells. J. Immunol. 188, 1442–1450
15. Wang, T., Ward, Y., Tian, L., Lake, R., Guedez, L., Stetler-Stevenson, W. G., and Kelly, K. (2005) CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood 105, 2836–2844
16. Kwakkenbos, M. J., Pouvels, W., Matmata, M., Stacey, M., Lin, H. H., Gordon, S., van Lier, R. A., and Hamann, J. (2005) Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells. J. Leukoc. Biol. 77, 112–119
17. Lublin, D. M., and Atkinson, J. P. (1989) Decay-accelerating factor: Biochemistry, molecular biology, and function. Annu. Rev. Immunol. 7, 35–58
18. Visser, L., de Groot, D. M., Vogel, G., Dulos, I., Teeuwen, L., Stebbins, K., Hamann, J., Owens, B. M., van Enennaam, H., Bos, E., and Boots, A. M. (2009) Therapeutic antibody targeting of CD97 in experimental arthritis: The role of antigen expression, shedding, and internalization on the pharmacokinetics of anti-CD97 monoclonal antibody 1B2. J. Immunol. 183, 4127–4134
19. Capasso, M., Durrant, L. G., Stacey, M., Gordon, S., Ramage, J., and Spendlove, I. (2006) Costimulation via CD55 on human CD4+ T cells mediated by CD97. J. Immunol. 177, 1070–1077
20. Lin, H. H., Stacey, M., Hamann, J., Gordon, S., and McKnight, A. J. (2000) Human EMR2, a novel EGF-TM7 molecule on chromosome 19p13.1, is closely related to CD97. Genomics 67, 188–200
21. Lukacik, P., Roversi, P., White, J., Esser, D., Smith, G. P., Billington, J., Williams, P. A., Rudd, P. M., Wormald, M. R., Harvey, D. J., Crispin, M. D., Badcliffe, C. M., Dwek, R. A., Evans, D. J., Morgan, B. P., et al. (2004) Complement regulation at the molecular level: The structure of decay-accelerating factor. Proc. Natl. Acad. Sci. U. S. A. 101, 1279–1284
22. Abbott, R. J., Spendlove, I., Roversi, P., Fitzgibbon, H., Knott, V., Teriete, P., McDonnell, I. M., Handford, P. A., and Lea, S. M. (2007) Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97–CD55. J. Biol. Chem. 282, 22023–22032
23. Tria, G., Mertens, H. D. T., Kakhalia, M., and Svergun, D. I. (2015) Advanced ensemble modelling of flexible macromolecules using X-ray solution scattering. IUCrJ 2, 207–217
24. Chen, J., Sawyer, N., and Regan, L. (2013) Protein-protein interactions: General trends in the relationship between binding affinity and interfacial buried surface area. Protein Sci. 22, 510–515
25. Qian, Y. M., Haino, M., Kelly, K., and Song, W. C. (1999) Structural characterization of mouse CD97 and study of its specific interaction with...
the murine decay-accelerating factor (DAF, CD55). *Immunology* 98, 303–311

27. Hamann, J., van Zeventer, C., Bijl, A., Molenaar, C., Tesselaar, K., and van Lier, R. A. (2000) Molecular cloning and characterization of mouse CD97. *Int. Immunol.* 12, 439–448

28. Hoek, R. M., de Launay, D., Kop, E. N., Yilmaz-Elis, A. S., Lin, F., Reedquist, K. A., Verbeek, J. S., Medof, M. E., Tak, P. P., and Hamann, J. (2010) Deletion of either CD55 or CD97 ameliorates arthritis in mouse models. *Arthritis Rheum.* 62, 1036–1042

29. Hamann, J., Wishaupt, J. O., van Lier, R. A., Smeets, T. J., Breedveld, F. C., and Tak, P. P. (1999) Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. *Arthritis Rheum.* 42, 650–658

30. Santiago, C., Celma, M. L., Stehle, T., and Casasnovas, J. M. (2010) Structure of the measles virus hemagglutinin bound to the CD46 receptor. *Nat. Struct. Mol. Biol.* 17, 124–129

31. Persson, B. D., Reiter, D. M., Marttila, M., Mei, Y. F., Casasnovas, J. M., Arnberg, N., and Stehle, T. (2007) Adenovirus type 11 binding alters the conformation of its receptor CD46. *Nat. Struct. Mol. Biol.* 14, 164–166

32. Karpus, O. N., Veninga, H., Hoek, R. M., Flierman, D., van Buul, J. D., Vandenaakker, C. C., van Bavel, E., Medof, M. E., van Lier, R. A., Reedquist, K. A., and Hamann, J. (2013) shear stress-dependent down-regulation of the adhesion-G protein-coupled receptor CD97 on circulating leukocytes upon contact with its ligand CD55. *J. Immunol.* 190, 3740–3748

33. Guo, S., Tang, Q., Yao, M., You, H., Le, S., Chen, H., and Yan, J. (2018) Structural-elastic determination of the force-dependent transition rate of biomolecules. *Chem. Sci.* 9, 5871–5882

34. Arac, D., Boucard, A. A., Boucard, A. A., Bolliger, M. F., Nguyen, J., Soltis, S. M., Sudhof, T. C., and Brunger, A. T. (2012) A novel evolutionarily conserved domain of cell-adhesion GPCRs mediates autoproteolysis. *EMBO J.* 31, 1364–1378

35. Liebscher, I., Schon, J., Petersen, S. C., Fischer, L., Auerbach, N., Demberg, L. M., Mogha, A., Coster, M., Simon, K. U., Rothemund, S., Monk, K. R., and Schoneberg, T. (2014) A tethered agonist within the ectodomain activates the adhesion-G protein-coupled receptors GPR126 and GPR133. *Cell Rep.* 9, 2018–2026

36. Wilde, C., Fischer, L., Lede, V., Kirchberger, J., Rothemund, S., Schoneberg, T., and Liebscher, I. (2016) The constitutive activity of the adhesion GPCR GPR114/ADGRG5 is mediated by its tethered agonist. *FASEB J.* 30, 666–673

37. Demberg, L. M., Rothemund, S., Schoneberg, T., and Liebscher, I. (2015) Identification of the tethered peptide agonist of the adhesion G protein-coupled receptor GPR64/ADGRG2. *Biochem. Biophys. Res. Commun.* 464, 743–747

38. Stoveken, H. M., Hajduczok, A. G., Xu, L., and Tall, G. G. (2015) Adhesion G protein-coupled receptors are activated by exposure of a cryptic tethered agonist. *Proc. Natl. Acad. Sci. U. S. A.* 112, 6194–6199

39. Imrsocher, S., Brix, S. R., Zipfel, S. L. H., Halder, L. D., Mutluthur, S., Wulf, S., Girdauskas, E., Reichenspurner, H., Stahl, R. A. K., Jungnickel, B., Wiech, T., Zipfel, P. F., and Skerka, C. (2019) Serum FHR1 binding to necrotic-type cells activates mononcic inflammasome and marks necrotic sites in vasculopathies. *Nat. Commun.* 10, 2961

40. Hilbig, D., Sittig, D., Hoffmann, F., Rothemund, S., Warmt, E., Quass, M., Sturmer, J., Seiler, L., Liebscher, I., Hoang, N. A., Kas, J. A., Banks, L., and Aust, G. (2018) Mechano-dependent phosphorylation of the PDZ-binding motif of CD97/ADGRE5 modulates cellular detachment. *Cell Rep.* 24, 1986–1995

41. White, J. P., Wran, C. D., Rao, R. R., Nair, S. K., Jedrychowski, M. P., You, J. S., Martinez-Redondo, V., Gygi, S. P., Rivas, J. L., Hornberger, T. A., Wu, Z. D., Glass, D. J., Piao, X. H., and Spiegelman, B. M. (2014) G protein-coupled receptor 95 regulates mechanical overload-induced muscle hypertrophy. *Proc. Natl. Acad. Sci. U. S. A.* 111, 15756–15761

42. Petersen, S. C., Luo, R., Liebscher, L., Giera, S., Jeong, S. I., Mogha, A., Ghideiellini, M., Feltl, M. L., Schoneberg, T., Piao, X. H., and Monk, K. R. (2015) The adhesion GPCR GPR126 has distinct, domain-dependent functions in Schwann cell development mediated by interaction with Laminin-211. *Neuron* 85, 755–769

43. Scholz, N., Gehring, J., Guan, C., Ljaschenko, D., Fischer, R., Lakshmanan, V., Kittel, R. J., and Langenhan, T. (2015) The adhesion GPCR latrophilin/CIIRL shapes mechanosensation. *Cell Rep.* 11, 866–874

44. Viurragf, A., Adhikari, R., Yeung, J. N., Yu, M. Y., and Tall, G. G. (2020) Mechanisms of adhesion G protein-coupled receptor activation. *J. Biol. Chem.* 295, 14065–14083

45. Yang, L. Y., Liu, X. F., Yang, Y., Yang, L. L., Liu, K. W., Yang, Y. B., Zhang, M., Tan, M. I., Cheng, S. M., Xu, Y. C., Yang, H. Y., Liu, Z. J., Song, G. J., and Huang, W. (2017) Biochemical features of the adhesion G protein-coupled receptor CD97 related to its auto-proteolysis and HeLa cell attachment activities. *Acta Pharmacol. Sin.* 38, 56–68

46. Ariescua, A. R., Lu, W., and Jones, E. Y. (2006) A time- and cost-efficient system for high-level protein production in mammalian cells. *Acta Crystallogr. D Biol. Crystallogr.* 62, 1243–1250

47. Hopkins, J. B., Gillilan, R. E., and Skou, S. (2017) BioXTAS RAW: Improvements to a free open-source program for small-angle X-ray scattering data reduction and analysis. *J. Appl. Crystallogr.* 50, 1545–1553

48. Petoukhov, M. V., Franke, D., Shkumatov, A. V., Tria, G., Kikhney, A. G., Gaida, M., Gorba, C., Mertens, H. D., Konarev, P. V., and Svergun, D. I. (2012) New developments in the ATSAS program package for small-angle scattering data analysis. *J. Appl. Crystallogr.* 45, 342–350

49. Franke, D., Petoukhov, M. V., Konarev, P. V., Panjkovich, A., Tuukkanen, A., Mertens, H. D. T., Kikhney, A. G., Hajizadeh, N. R., Franklin, J. M., Jeffreys, C. M., and Svergun, D. I. (2017) Atas 2.8: A comprehensive data analysis suite for small-angle scattering from macromolecular solutions. *J. Appl. Crystallogr.* 50, 1212–1225

50. Svergun, D. I., Petoukhov, M. V., and Koch, M. H. (2001) Determination of domain structure of proteins from X-ray scattering data analysis. *Biophys. J.* 80, 2946–2953

51. Winter, G., Lobley, C. M., and Prince, S. M. (2013) Decision making in xi2a. *Acta Crystallogr. D Biol. Crystallogr.* 69, 1260–1273

52. Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., and et al. (2010) PHENIX: A comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D Biol. Crystallogr.* 66, 213–221

53. Ensmale, P., Lobkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* 66, 486–501